局部晚期乳腺癌新辅助同期放化疗的II期临床试验
该前瞻性II期试验纳入32例局部晚期乳腺癌患者,在新辅助化疗(FEC方案3周期后多西他赛周疗9周期)期间同期给予区域放疗(45 Gy/25次+5.4 Gy/5次),随后行改良根治术。
要点
- 同期新辅助放化疗较单纯新辅助化疗显著提高pCR(14% vs 22%,P<.001)。
- 3年无病生存(69% vs 81%,P=.186)和总生存(74% vs 89%,P=.162)无显著差异。
- 毒性包括25%患者出现3级肺炎和25%出现皮炎,另有1例死亡。
核心结论
- 在新辅助化疗中加入同期放疗可显著提高局部晚期乳腺癌的病理完全缓解率。
- 同期放化疗未显著改善3年无病生存和总生存,需前瞻性随机试验进一步验证。
研究设计与样本
- 前瞻性II期试验,2009至2011年招募32例局部晚期乳腺癌患者。
- 患者接受每3周一次5-氟尿嘧啶(500 mg/m2)、表柔比星(100 mg/m2)和环磷酰胺(500 mg/m2)共3周期,随后每周多西他赛(35 mg/m2)共9周期。
- 区域放疗(45 Gy/25次+5.4 Gy/5次)与多西他赛同期进行,之后行改良根治术。
- 由盲法统计学家事后将患者按年龄、分期和分子亚型与同期队列(新辅助化疗+改良根治术+辅助区域放疗)进行倾向性评分匹配。
主要发现
- 同期放化疗组pCR为22%,对照组为14%,差异显著(P<.001)。
- 3年无病生存率同期组69% vs 对照组81%(P=.186,风险比0.51)。
- 3年总生存率同期组74% vs 对照组89%(P=.162,风险比0.46)。
- 毒性包括25%患者出现3级肺炎、25%出现皮炎,以及1例死亡。
关键数值与推荐
- 同期放化疗组pCR 22% vs 对照组14%(P<.001)。
- 3年无病生存:69% vs 81%(P=.186,HR 0.51)。
- 3年总生存:74% vs 89%(P=.162,HR 0.46)。
- 3级肺炎发生率25%,皮炎发生率25%,死亡1例。
临床怎么用
- 对于局部晚期乳腺癌,新辅助化疗同期联合区域放疗可提高病理缓解率,但需警惕肺炎和皮炎等毒性。
- 该方案尚不能常规推荐,需等待采用其他放射增敏紫杉类药物的随机试验结果以平衡疗效与毒性。
局限性
- 为II期单臂试验,样本量小(32例),对照组为事后倾向性评分匹配的非随机队列。
- 3年生存分析未显示统计学显著差异,研究把握度有限。
- 毒性较高,包括25%的3级肺炎和1例治疗相关死亡。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To evaluate whether concurrent neoadjuvant radiation added to standard chemotherapy could increase the pathologic complete response (pCR) to treatment for locally advanced breast cancer (LABC). METHODS AND MATERIALS: This prospective phase 2 trial recruited 32 LABC patients from 2009 to 2011. Patients received neoadjuvant every-3-weekly 5-fluorouracil (500 mg/m2), epirubicin (100 mg/m2), and cyclophosphamide (500 mg/m2) for 3 cycles, followed by weekly docetaxel (35 mg/m2) for 9 cycles. Regional radiation (45 Gy/25 plus 5.4 Gy/5) was delivered concurrently with docetaxel, then modified radical mastectomy. Patients were matched post hoc by a blinded statistician to a concurrent cohort treated with neoadjuvant chemotherapy, modified radical mastectomy, and adjuvant regional radiation. RESULTS: Thirty of 32 patients completed treatment. Twenty-seven were successfully matched by propensity score to 81 control patients by age, stage, and molecular subtype. The concurrent chemoradiation produced a significant increase in pCR (14% vs 22%, P<.001) but no statistically significant difference in disease-free and overall survival at 3 years (respectively, 69% vs 81%, P=.186, hazard ratio 0.51; and 74% vs 89%, P=.162, hazard ratio 0.46). Toxicity included 25% of patients with grade 3 pneumonitis and 25% of patients with dermatitis, and 1 death. CONCLUSIONS: Concurrent neoadjuvant radiation added to radiosensitizing chemotherapy significantly improved pCR. A prospective randomized clinical trial is warranted to exploit the improved response seen with concurrent therapy but using another radio-sensitizing taxane, to better minimize treatment-related toxicity and determine its impact on overall survival.
引用
- Brackstone M, Palma D, Tuck AB, et al. Concurrent Neoadjuvant Chemotherapy and Radiation Therapy in Locally Advanced Breast Cancer. Int J Radiat Oncol Biol Phys. 2017. PMID: 28870785. doi:10.1016/j.ijrobp.2017.06.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。